SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs

13Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Perturbations of the circadian clock are linked to multiple diseases, including cancers. Pharmacological activation of REV-ERB nuclear receptors, the core components of the circadian clock, has antitumor effects on various malignancies, while the impact of SR9009 on prostate cancer (PCa) remains unknown. Here, we found that SR9009 was specifically lethal to PCa cell lines but had no cytotoxic effect on prostate cells. SR9009 significantly inhibited colony formation, the cell cycle, and cell migration and promoted apoptosis in PCa cells. SR9009 treatment markedly inhibited prostate cancer subtype 1 (PCS1), the most lethal and aggressive PCa subtype, through FOXM1 pathway blockade, while it had no impacts on PCS2 and PCS3. Seven representative genes, including FOXM1, CENPA, CENPF, CDK1, CCNB1, CCNB2, and BIRC5, were identified as the shared genes involved in the FOXM1 pathway and PCS1. All of these genes were upregulated in PCa tissues, associated with worse clinicopathological outcomes and downregulated after SR9009 treatment. Nevertheless, knockdown or knockout of REV-ERB could not rescue the anticancer effect of SR9009 in PCa. Further analysis confirmed that it was LXRα rather than REV-ERBs which has been activated by SR9009. The expression levels of these seven genes were changed correspondingly after LXRα knockdown and SR9009 treatment. An in vivo study validated that SR9009 restrained tumor growth in 22RV1 xenograft models and inhibited FOXM1 and its targeted gene expression. In summary, SR9009 can serve as an effective treatment option for highly aggressive and lethal PCS1 tumors through mediating the LXRα/FOXM1 pathway independently of REV-ERBs.

References Powered by Scopus

Cancer Statistics, 2021

18249Citations
N/AReaders
Get full text

Molecular portraits of human breast tumours

12937Citations
N/AReaders
Get full text

Increased survival with enzalutamide in prostate cancer after chemotherapy

3900Citations
N/AReaders
Get full text

Cited by Powered by Scopus

FOXM1: A small fox that makes more tracks for cancer progression and metastasis

41Citations
N/AReaders
Get full text

ADP-dependent glucokinase controls metabolic fitness in prostate cancer progression

8Citations
N/AReaders
Get full text

Inhibiting Rev-erbα-mediated ferroptosis alleviates susceptibility to myocardial ischemia-reperfusion injury in type 2 diabetes

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Xu, H., Zhang, J., Zheng, X., Tan, P., Xiong, X., Yi, X., … Yang, L. (2022). SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs. Cell Death and Disease, 13(11). https://doi.org/10.1038/s41419-022-05392-6

Readers over time

‘22‘23‘2401234

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Researcher 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

40%

Biochemistry, Genetics and Molecular Bi... 2

40%

Engineering 1

20%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free
0